Related Experiment Video
Updated: Aug 8, 2026
Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
Published on: March 25, 2016
Malignant leukemic cell separation by iron colloid immunomagnetic adsorption
C J Biéva1, F J Vander Brugghen, P A Stryckmans
1Service de Médecine Interne, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Belgium.
Insights
This study presents an immunomagnetic assay for bone marrow purging in leukemia patients undergoing autologous stem cell transplantation. The assay effectively removes leukemic cells while preserving essential myeloid progenitors.
Area of Science:
- Hematology
- Immunology
- Biotechnology
Background:
- Autologous bone marrow transplantation (ABMT) is a crucial therapy for leukemia.
- Effective purging of residual leukemic cells from bone marrow is essential for successful ABMT.
- Current purging methods face challenges in efficiency, cost, and progenitor cell recovery.
Purpose of the Study:
- To develop and evaluate an immunomagnetic assay for efficient bone marrow purging of leukemic cells.
- To assess the efficacy of the assay in removing common acute lymphoblastic leukemia antigen (CALLA)-positive cells.
- To determine the impact of the assay on the recovery of clonogenic myeloid progenitors.
Main Methods:
- Utilized an iron colloidal suspension coated with a CD10 monoclonal antibody (MoAb) targeting CALLA.
- Labeled leukemic cell lines (NALM-6) with Hoechst 33342 and incubated with MoAb-coated iron particles.
- Assessed purging efficiency via log depletion and evaluated recovery of granulocyte-macrophage colony-forming units (CFU-GM).
Main Results:
- Achieved a purging effect greater than 3.5 logs for CALLA-positive cells at a concentration of 2000 cells/microliter.
- Demonstrated consistent depletion across three successive treatment rounds.
- Reported approximately 75% recovery of clonogenic myeloid progenitors (CFU-GM).
Conclusions:
- The described immunomagnetic assay is simple, efficient, and cost-effective for bone marrow purging.
- The assay demonstrates high specificity, removing target leukemic cells without significant depletion of essential myeloid progenitors.
- This method holds promise for clinical application in ABMT for leukemia patients, offering sterile handling and minimal processing time.
Abstract:
We describe an immunomagnetic assay applicable to bone marrow purging of leukemic patients before an autologous bone marrow transplantation. An iron colloidal suspension with a CD10 monoclonal antibody (MoAb) against the common acute lymphoblastic leukemia antigen (CALLA) covalently bound to the surface of the particles has been used. NALM-6 cells, a pre-B leukemic cell line expressing the CALLA, were labeled with supravital DNA dye (Hoechst 33342), mixed with peripheral blood, and incubated with the MoAb coated to iron particles. Using this reagent, at a cell concentration of 2000/microliters, a purging effect greater than 3.5 logs is observed with 0.1 mg of coated particles. Three successive rounds of treatment with the same coated particles at the same dose showed approximately the same depletion after each treatment. The recovery of clonogenic myeloid progenitors (granulocyte-macrophage colony-forming units; CFU-GM) is around 75%. No depletion was observed when the iron particles were not attached to the CD10 MoAb, or when they were attached to a MoAb not recognizing CD10+ cells. A comparison with another commercially available magnetic support was also performed in order to evaluate the performance of our assay, which appears simple, efficient, cheap, and capable of handling large volumes of cells in sterile conditions and minimal time.
